Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00604786 · ClinicalTrials.gov registry record · NA
The Effect of Omalizumab on Responses to Cat Allergen Challenge
A NA study of Allergic Rhinitis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT00604786: Completed NA study of Allergic Rhinitis, sponsored by Johns Hopkins University.
NCT00604786 is a NA study of Allergic Rhinitis that has completed, run by Johns Hopkins University. The registered enrollment target is 18 participants, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00604786, a NA study of Allergic Rhinitis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected before cells in the nose or skin.
Primary Outcome
Flow cytometry in mean fluorescence units. 100%\*\[(3.5 month value minus baseline value)/baseline value\]
Conditions Studied
Interventions
- DRUG placebo
- DRUG omalizumab
Study Locations (1)
Maryland
- Johns Hopkins Asthma and Allergy Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-07 |
| Est. Completion | 2009-01 |
| Phase | NA |
What the finished NCT00604786 record still lists
NCT00604786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 104-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00604786 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00604786 about?
NCT00604786 is a clinical study titled "The Effect of Omalizumab on Responses to Cat Allergen Challenge". This research is being done to study the effects of the drug omalizumab (Xolair) in people with cat allergies. The investigators will use omalizumab to study changes in the cells in the nose, skin and blood that cause allergies. The investigators predict that cells in the blood will be effected befo...
What is the current status of trial NCT00604786?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2007-07. Estimated completion is 2009-01.
What conditions does trial NCT00604786 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00604786?
The interventions under investigation include: placebo (DRUG), omalizumab (DRUG).
Who is sponsoring clinical trial NCT00604786?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00604786 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00604786's enrollment target sits among peer trials
18 22nd of 23 higher than 2 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Effects of Diesel Exhaust Followed by Administration of Nasal Spray Flu Vaccine on Individuals With & Without Allergies
COMPLETED · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia